Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company covers the event date of August 1, 2008. The report details the completion of a previously announced strategic divestiture.
Key Financial Metrics
- Transaction Value: Gross purchase price of approximately $4.1 billion in cash.
- Buyer: Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista Capital Partners.
- Asset Type: ConvaTec business (divested unit).
- Liabilities: The Buyer assumed certain liabilities relating to the Business as part of the transaction.
The filing text does not provide specific values for the Company's overall revenue, profit, cash flow, margins, or total debt levels outside the context of this specific transaction.
Material Changes
The primary material change is the exit from the ConvaTec business. The transaction was effected through the transfer of outstanding capital stock of certain indirect subsidiaries and specified assets and liabilities. The purchase price includes an estimated post-closing adjustment based on the closing working capital of the Business, with total proceeds subject to further adjustment based on actual figures.
Guidance, Outlook, and Risks
The filing incorporates Unaudited Pro Forma Financial Information (Exhibit 99.2) which details the operating results of the divested Business as "Amounts Transferred to Discontinued Operations." No forward-looking guidance or specific risk factors regarding the Company's future operations are detailed in the text of this specific filing, other than the standard reference to the Purchase Agreement for complete terms.
Investor Verification Checklist
- Verify the final purchase price after the actual closing working capital adjustment is calculated.
- Review the Unaudited Pro Forma Financial Information (Exhibit 99.2) to understand the impact on the Company's financial statements.
- Examine the Stock and Asset Purchase Agreement (filed as Exhibit 10.1 in the May 7, 2008 Form 8-K) for specific terms regarding assumed liabilities.
- Confirm the classification of the ConvaTec business results as discontinued operations in future earnings reports.